

# Influenza Vaccine Products for the 2026–2027 Influenza Season

| Manufacturer | Trade Name<br>(vaccine abbreviation) <sup>1</sup> | How Supplied                          | Mercury<br>Content<br>(mcg Hg/0.5 mL) | Age Range                        | CVX<br>Code | Vaccine Product<br>Billing Code <sup>2</sup> |
|--------------|---------------------------------------------------|---------------------------------------|---------------------------------------|----------------------------------|-------------|----------------------------------------------|
|              |                                                   |                                       |                                       |                                  |             | CPT                                          |
| AstraZeneca  | FluMist (LAIV3)                                   | 0.2 mL (single-use nasal spray)       | 0                                     | 2 through 49 years               | 111         | 90660                                        |
|              |                                                   |                                       |                                       |                                  | 333*        | NA*                                          |
| GSK          | Fluarix (IIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                     | 6 months & older <sup>3</sup>    | 140         | 90656                                        |
|              | FluLaval (IIV3)                                   | 0.5 mL (single-dose syringe)          | 0                                     | 6 months & older <sup>3</sup>    | 140         | 90656                                        |
| Moderna      | mFlusiva (mRNA)                                   | 0.38 mL (single-dose syringe)         | 0                                     | 50 years & older                 | TBD         | 90616                                        |
| Sanofi       | Flublok (RIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                     | 9 years & older                  | 155         | 90673                                        |
|              | Fluzone (IIV3)                                    | 0.5 mL (single-dose syringe)          | 0                                     | 6 months & older <sup>3</sup>    | 140         | 90656                                        |
|              |                                                   | 0.5 mL (single-dose vial)             | 0                                     | 6 months & older <sup>3</sup>    | 140         | 90656                                        |
|              |                                                   | 5.0 mL multi-dose vial (0.25 mL dose) | 25                                    | 6 through 35 months <sup>3</sup> | 141         | 90657                                        |
|              |                                                   | 5.0 mL multi-dose vial (0.5 mL dose)  | 25                                    | 6 months & older                 | 141         | 90658                                        |
|              | Fluzone High-Dose (HD-IIV3)                       | 0.5 mL (single-dose syringe)          | 0                                     | 65 years & older <sup>4</sup>    | 135         | 90662                                        |
| CSL Seqirus  | Fluad (aIIV3)                                     | 0.5 mL (single-dose syringe)          | 0                                     | 65 years & older <sup>4</sup>    | 168         | 90653                                        |
|              | Flucelvax (ccIIV3)                                | 0.5 mL (single-dose syringe)          | 0                                     | 6 months & older <sup>3</sup>    | 153         | 90661                                        |

## NOTES

1. All 2026–2027 seasonal influenza vaccines are trivalent. IIV = egg-based inactivated influenza vaccine (injectable); where necessary to refer to cell culture-based vaccine, the prefix “cc” is used (e.g., ccIIV); RIV = recombinant hemagglutinin influenza vaccine (injectable); aIIV = adjuvanted inactivated influenza vaccine. mRNA = messenger RNA-based influenza vaccine (standard abbreviation TBD)

2. An administration code should always be reported in addition to the vaccine product code. Note: Third party payers may have specific policies and guidelines that might require providing additional information on their claim forms.

3. Dosing for infants and children age 6 through 35 months:

- Fluarix 0.5 mL
- Flucelvax 0.5 mL
- FluLaval 0.5 mL
- Fluzone 0.25 mL or 0.5 mL

4. Beginning in 2024, CDC states HD-IIV and aIIV are acceptable options for solid organ transplant recipients age 18 through 64 years receiving immunosuppressive medications. There is no preference over other age-appropriate IIV or RIV.

\* Self- or caregiver-administered at home

